CA2260756A1 - System for genetically treating cardiac conduction disturbances - Google Patents

System for genetically treating cardiac conduction disturbances

Info

Publication number
CA2260756A1
CA2260756A1 CA002260756A CA2260756A CA2260756A1 CA 2260756 A1 CA2260756 A1 CA 2260756A1 CA 002260756 A CA002260756 A CA 002260756A CA 2260756 A CA2260756 A CA 2260756A CA 2260756 A1 CA2260756 A1 CA 2260756A1
Authority
CA
Canada
Prior art keywords
conduction
genetic material
delivering
heart
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002260756A
Other languages
French (fr)
Other versions
CA2260756C (en
Inventor
Kenneth B. Stokes
Josee Morissette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic, Inc.
Kenneth B. Stokes
Josee Morissette
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc., Kenneth B. Stokes, Josee Morissette filed Critical Medtronic, Inc.
Priority claimed from PCT/US1997/006103 external-priority patent/WO1998002150A1/en
Publication of CA2260756A1 publication Critical patent/CA2260756A1/en
Application granted granted Critical
Publication of CA2260756C publication Critical patent/CA2260756C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0082—Catheter tip comprising a tool
    • A61M25/0084—Catheter tip comprising a tool being one or more injection needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/329—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles characterised by features of the needle shaft
    • A61M5/3291—Shafts with additional lateral openings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides delivery systems for delivering conduction protein genetic material to cardiac cells in localized areas of the heart to improve the conductance therein. More specifically, there is provided a system for delivering connexin proteins or nucleic acid molecules encoding connexin proteins to a site in the heart which has been determined by mapping procedures to have a conduction disturbance. For cases where conduction is impaired, selected genetic material is delivered by Applicants' delivery system to cells around the disturbance area, in order to enhance overall conductivity patterns; in other cases, genetic material is selected to slow conduction in affected areas, so as to prevent, e.g., brady-tachy syndrome.
CA002260756A 1996-07-17 1997-04-04 System for genetically treating cardiac conduction disturbances Expired - Fee Related CA2260756C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68227796A 1996-07-17 1996-07-17
US08/682,277 1996-07-17
PCT/US1997/006103 WO1998002150A1 (en) 1996-07-17 1997-04-04 System for genetically treating cardiac conduction disturbances

Publications (2)

Publication Number Publication Date
CA2260756A1 true CA2260756A1 (en) 1998-01-22
CA2260756C CA2260756C (en) 2007-07-10

Family

ID=38254967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002260756A Expired - Fee Related CA2260756C (en) 1996-07-17 1997-04-04 System for genetically treating cardiac conduction disturbances

Country Status (1)

Country Link
CA (1) CA2260756C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740699A1 (en) * 2004-04-29 2007-01-10 GOLLOB, MIchael H. Connexin 40 tissue specific gene mutations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740699A1 (en) * 2004-04-29 2007-01-10 GOLLOB, MIchael H. Connexin 40 tissue specific gene mutations
EP1740699A4 (en) * 2004-04-29 2008-10-15 Michael H Gollob Connexin 40 tissue specific gene mutations

Also Published As

Publication number Publication date
CA2260756C (en) 2007-07-10

Similar Documents

Publication Publication Date Title
US5198423A (en) Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
IL118201A0 (en) Erythropoietin free of animal proteins processes for production and use thereof
AU7587696A (en) Differentiation-suppressive polypeptide
Park et al. Overexpression of HSP25 reduces the level of TNFα‐induced oxidative DNA damage biomarker, 8‐hydroxy‐2′‐deoxyguanosine, in L929 cells
KR960703433A (en) A TRUNCATED KERATINOCYTE GROWTH FACTOR (KGF) HAVING INCREASED BIOLOGICAL ACTIVITY With Increased Biological Activity
CA2097185A1 (en) Viral recombinant vectors for expression in muscle cells
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
FR2738151B1 (en) ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE MDM2 PROTEIN, AND THEIR USE IN THE TREATMENT OF CANCERS
Takahashi-Nakamura et al. Purification and characterization of an inhibitor of calcium-activated neutral protease from rabbit skeletal muscle
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
ATE293700T1 (en) ADENOVIRUS WITH GLUTATHIONE PEROXYDATE GENES
Melloni et al. Identity in Molecular Structure between" Differentiation Enhancing Factor" of Murine Erithroleukemia Cells and the 30-kDa Heparin-Binding Protein of Developing Rat Brain
CA2186423A1 (en) Protein which induces interferon-gamma production by immunocompetent cell
CHRISTOMANOU et al. Isolation of two forms of an activator protein for the enzymic sphingomyelin degradation from human Gaucher spleen
Miyazono et al. A platelet factor stimulating the proliferation of vascular endothelial cells: partial purification and characterization
WO1995030001A3 (en) Novel p-selectin ligand protein
ZA895840B (en) N-2,3-butadienyl tri-and tetraaminoalkane derivatives
DE69533796D1 (en) DNA ENCODING THE GLUTAMATE-DEPENDENT CHLORIDE CHANNELS
CA2260756A1 (en) System for genetically treating cardiac conduction disturbances
Medda et al. Identity of esterase-22 and egasyn, the protein which complexes with microsomal β-glucuronidase
Rehm Enzymatic deglycosylation of the dendrotoxin‐binding protein
WO1999032625A3 (en) Nucleotide and protein sequence of mammastatin and methods of use
WO2000057864A3 (en) Cyclic glycerophosphates and analogs thereof
WO2000017375A3 (en) Method to treat haemophilia by in vivo gene therapy with retroviral vectors
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed